Cargando…
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
BACKGROUND: The role and clinical value of ERβ1 expression is controversial and recent data demonstrates that many ERβ antibodies are insensitive and/or non-specific. Therefore, we sought to comprehensively characterize ERβ1 expression across all sub-types of breast cancer using a validated antibody...
Autores principales: | Reese, Jordan M, Suman, Vera J, Subramaniam, Malayannan, Wu, Xianglin, Negron, Vivian, Gingery, Anne, Pitel, Kevin S, Shah, Sejal S, Cunliffe, Heather E, McCullough, Ann E, Pockaj, Barbara A, Couch, Fergus J, Olson, Janet E, Reynolds, Carol, Lingle, Wilma L, Spelsberg, Thomas C, Goetz, Matthew P, Ingle, James N, Hawse, John R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196114/ https://www.ncbi.nlm.nih.gov/pubmed/25288324 http://dx.doi.org/10.1186/1471-2407-14-749 |
Ejemplares similares
-
Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
por: Hawse, John R., et al.
Publicado: (2013) -
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
por: Wu, Xianglin, et al.
Publicado: (2011) -
The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014) -
ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017) -
Retinoblastoma binding protein-1 (RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation
por: Monroe, David G, et al.
Publicado: (2010)